pI: 8.6807 |
Length (AA): 592 |
MW (Da): 66253 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
235 | 271 | 3k2c (A) | 111 | 145 | 51.00 | 0.39 | 0.7 | 0.4763 | 1.02 |
307 | 436 | 3cw1 (K) | 14 | 177 | 31.00 | 0.00091 | 1 | 0.375395 | 0.8 |
359 | 440 | 4c7q (A) | 3 | 84 | 38.00 | 0 | 1 | 0.754813 | -1.59 |
504 | 572 | 5d2q (A) | 116 | 181 | 20.00 | 0 | 0.01 | 0.443854 | -1.94 |
517 | 589 | 5hmo (A) | 815 | 887 | 30.00 | 0.0013 | 0.01 | 0.662111 | -2.52 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite. | Gregory Hehl AB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 Oocyst, ME49 Bradyzoite. | Fritz HM Sibley/Greg |
Gregory | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Sibley/Greg | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Ortholog group members (OG5_129019)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G53720 | cyclophilin 59 |
Babesia bovis | BBOV_III003390 | RNA recognition motif domain containing protein |
Brugia malayi | Bm1_01380 | hypothetical protein |
Caenorhabditis elegans | CELE_F39H2.2 | Protein SIG-7, isoform B |
Cryptosporidium hominis | Chro.80276 | cyclophilin-RNA interacting protein |
Cryptosporidium parvum | cgd8_2350 | cyclophilin-RNA interacting protein, putative |
Dictyostelium discoideum | DDB_G0292710 | hypothetical protein |
Drosophila melanogaster | Dmel_CG5808 | CG5808 gene product from transcript CG5808-RA |
Echinococcus granulosus | EgrG_000604500 | STIP1 y and U box containing protein 1 |
Entamoeba histolytica | EHI_054760 | peptidyl prolyl cis-trans isomerase, putative |
Echinococcus multilocularis | EmuJ_000679400 | peptidyl prolyl cis trans isomerase 4 |
Echinococcus multilocularis | EmuJ_000680200 | peptidyl prolyl cis trans isomerase 4 |
Echinococcus multilocularis | EmuJ_000604500 | STIP1 y and U box containing protein 1 |
Homo sapiens | ENSG00000131013 | peptidylprolyl isomerase (cyclophilin)-like 4 |
Loa Loa (eye worm) | LOAG_08216 | SIG-7 protein |
Mus musculus | ENSMUSG00000015757 | peptidylprolyl isomerase (cyclophilin)-like 4 |
Neospora caninum | NCLIV_045550 | RNA recognition motif-containing protein, putative |
Oryza sativa | 4341804 | Os06g0670500 |
Plasmodium berghei | PBANKA_1425000 | RNA-binding protein, putative |
Plasmodium falciparum | PF3D7_0812500 | RNA-binding protein, putative |
Plasmodium knowlesi | PKNH_1428100 | RNA-binding protein, putative |
Plasmodium vivax | PVX_123145 | hypothetical protein, conserved |
Plasmodium yoelii | PY01794 | putative peptidyl prolyl cis-trans isomerase with RNA binding region |
Schistosoma japonicum | Sjp_0216410 | ko:K09561 STIP1 homology and U-box containing protein 1, putative |
Schistosoma japonicum | Sjp_0120600 | STIP1 homology and U box-containing protein 1, putative |
Schistosoma japonicum | Sjp_0091550 | ko:K01802 peptidylprolyl isomerase [EC5.2.1.8], putative |
Schistosoma japonicum | Sjp_0090860 | STIP1 homology and U box-containing protein 1, putative |
Schistosoma mansoni | Smp_165540 | peptidyl-prolyl cis-trans isomerase |
Schmidtea mediterranea | mk4.003843.00 | |
Schmidtea mediterranea | mk4.001968.01 | |
Schmidtea mediterranea | mk4.014953.00 | |
Toxoplasma gondii | TGME49_227850 | peptidyl-prolyl cis-trans isomerase, cyclophilin-type domain-containing protein |
Theileria parva | TP03_0334 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_106810 | peptidyl-prolyl cis-trans isomerase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
CELE_F39H2.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_F39H2.2 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_F39H2.2 | Caenorhabditis elegans | sterile | wormbase |
TGME49_227850 this record | Toxoplasma gondii | Probably essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.